Cytokine production patterns in cervical intraepithelial neoplasia: Association with human papillomavirus infection

Journal of the National Cancer Institute

Volumn 89, Issue 3, 1997, Pages 245-250

  Clerici, Mario ^a,b   Merola, Marina ^c   Ferrario, Enrica ^a,b   Trabattoni, Daria ^a,b   Villa, Maria Luisa ^a,b   Stefanon, Bernardina ^c   Venzon, David J ^d   Shearer, Gene M ^d   De Palo, Giuseppe ^c   Clerici, Enrico ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4;

ADULT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; PROTEIN SECRETION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

EID: 0031019375     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.3.245     Document Type: Article

References (39)

1. Ferenczy A. Epidemiology and clinical pathophysiology of condylomata acuminata. Am J Obstet Gynecol 1995;172:1331-9.
2. Wright TC Jr, Richart RM. Role of human papillomavirus in the pathogenesis of genital tract warts and cancer. Gynecol Oncol 1990;37:151-64.
3. Gissmann L. Human papillomaviruses and genital cancer. Semin Cancer Biol 1992;3:253-61.
4. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
5. Mosmann TR, Coffman RI. Two types of mouse T helper cell clone: implication for immune regulation. Immunol Today 1987;8:223-6.
6. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991;12:256-7.
7. Clerici M, Shearer GM. A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-11.
8. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575-81.
9. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA 1995; 273:1933-6.
10. Lucey DR, Clerici M, Shearer GM. Type 1/type 2 cytokines in human infectious, neoplastic and inflammatory diseases. Clin Microbiol Rev 1996;9:532-62.
11. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178: 1223-30.
12. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ 3rd, McKinney TG, Schreiber RD, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-74.
13. Gately MK, Worrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994;6:157-67.
14. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, et al. Restoration of HIV-specific cell-mediated immune response by interleukin-12 in vitro. Science 1993;262: 1721-4.
15. Bost KL, Bieligk SC, Jaffe BM. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J Immunol 1995;154:718-29.
16. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995;155: 2240-7.
17. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 1995;154:1280-6.
18. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, et al. Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180:2371-6.
19. Via CS, Tsokos GC, Stocks NI, Clerici M, Shearer GM. Human in vitro allogeneic responses. Demonstration of three pathways of T helper cell activation. J Immunol 1990;44: 2524-8.
20. The revised Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda Workshop. Acta Cytol 1992;36: 273-6.
21. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
22. Muluk SC, Clerici M, Via CS, Weir MR, Kimmel PL, Shearer GM. Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplant 1991;52:284-91.
23. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994;145:18-25.
24. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995;55:3847-53.
25. Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, et al. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995;41: 111-21.
26. Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 1995;61:780-5.
27. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995;63:366-71.
28. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 1995;146:317-22.
29. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994;56:755-60.
30. Kruger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Huls C, Blankenstein T, et al. Expression of interleukin 10 in human melanoma. Br J Cancer 1994;70:1182-5.
31. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177: 1199-204.
32. Seder RA, Paul WE, Davis MM, Fazekas de St. Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992;176:1091-8.
33. Salazar-Onfray F, Petersson M, Franksson L, Matsuda M, Blankenstein T, Karre K, et al. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 1995;154:6291-8.
34. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993;11:165-90.
35. Lucey DR, Melcher GP, Hendrix CW, Zajac RA, Goetz DW, Butzin CA, et al. Human immunodeficiency virus infection in the US Air Force: seroconversion, clinical staging, and assessment of a T helper functional assay to pre-diet change in CD4+ T cell counts. J Infect Dis 1991;164:631-7.
36. Dolan MJ, Clerici M, Blatt SP, Hendrix CW, Melcher GP, Boswell RN, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995;172:79-87.
37. Clerici M, Roilides E, Butler KM, DePalma L, Venzon D, Shearer GM, et al. Changes in T-helpercell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. Blood 1992;80:2196-202.
38. Gorelik L, Prokhorova A, Mokyr MB. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 1994;39:117-26.
39. Clerici M, Ferrario E, Trabattoni D, Viviani S, Bonfanti V, Venzon DJ, et al. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur J Cancer 1994;30A:1464-70.